冠昊生物科技股份有限公司 关于补缴税款的公告 本公司及董事会全体人员保证信息披露的内容真实、准确和完整，没有虚 假记载、误导性陈述或者重大遗漏。 冠昊生物科技股份有限公司(以下简称"公司")近期根据税务部门要求，对 涉税事项开展自查。现将有关情况公告如下： 一、基本情况 经自查，公司需补缴税款及滞纳金合计 1,729.81 万元，其中补缴税款 1,491.44 万元，滞纳金 238.37 万元（金额为初步测算，最终以税务局系统金额为准）。 公司将按照要求于 10 个工作日内将上述税款及滞纳金全部缴纳完毕，本次补缴 不涉及行政处罚。 证券代码：300238 证券简称：冠昊生物 公告编号：2026-002 二、对公司的影响及风险提示 根据《企业会计准则第 28 号——会计政策、会计估计变更和差错更正》相 关规定，上述补缴税款事项不属于前期会计差错，不涉及前期财务数据追溯调整。 上述补缴的税款及滞纳金将计入公司 2025 年当期损益，对公司 2025 年度归属于 上市公司股东的净利润的具体影响，最终以 2025 年度经审计的财务报表为准。 本次补缴税款事项不会影响公司的正常经营，敬请广大投资者注意投资风险。 特此公 ...

证券代码：300238 证券简称：冠昊生物 公告编号：2026-001 冠昊生物科技股份有限公司（以下简称"公司"）独立董事韩俊梅女士自 2020 年 3 月 13 日起担任公司独立董事，连续任职时间已满六年。根据《上市公 司独立董事管理办法》相关规定："独立董事每届任期与上市公司其他董事任期 相同，任期届满，可以连选连任，但是连续任职不得超过六年。"故韩俊梅女士 期满离任后不再担任公司第六届董事会独立董事以及董事会各专门委员会中的 全部职务。截至本公告披露日，韩俊梅女士未持有公司股份，不存在应当履行而 未履行的承诺事项。 鉴于韩俊梅女士的离任将导致公司独立董事占董事会成员的比例低于三分 之一，董事会相关专门委员会中独立董事未过半数，为保证公司董事会规范运作， 根据《公司法》《上市公司独立董事管理办法》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》及《公司章程》等相关规定，韩 俊梅女士需继续履行独立董事职责及其在董事会各专门委员会中的相关职责，直 至公司股东会选举产生新任独立董事。公司董事会将按照相关法律法规要求，尽 快完成独立董事及相关董事会专门委员会职务的补选工作。 韩俊梅女 ...

Group 1 - The core point of the article is that Guanxiao Biological has reported its total number of shareholders as of February 13, 2026, which stands at 29,793 households [2]

Group 1 - The core point of the article is that Guanhao Biological (300238) reported a total of 30,667 shareholders as of January 30, 2026 [1]

Group 1 - The core point of the article is that Guanhao Biological (300238) reported a total of 31,018 shareholders as of January 20, 2026 [1]

Core Viewpoint - Guanhao Biological (300238.SZ) has stated that it has not yet established a partnership with Qiangnao Technology, and any relevant information should be based on the announcements published by the company in designated information disclosure media [1] Company Information - The company confirmed on its interactive platform that there is currently no collaboration with Qiangnao Technology [1] - The company emphasized that stakeholders should refer to official announcements for accurate information [1]

Group 1 - The core viewpoint of the article is that Guanhao Biological has confirmed that its current production and operational activities are normal and orderly, with no undisclosed significant risk matters [2] Group 2 - The company responded to investor inquiries on its interactive platform, reinforcing its operational stability [2] - The statement indicates transparency in the company's communication with investors regarding its risk status [2]

Group 1 - The core viewpoint of the news is that Guanhao Biological has shown significant stock price performance and financial metrics, indicating potential growth and investment interest [1][2]. - As of January 8, Guanhao Biological's stock price increased by 22.82% year-to-date, with a market capitalization of 4.51 billion yuan [1]. - The company reported a revenue of 293 million yuan for the period from January to September 2025, reflecting a year-on-year growth of 5.52%, while the net profit attributable to shareholders decreased by 4.02% to 26.72 million yuan [2]. Group 2 - Guanhao Biological's main business segments include medical devices (73.28% of revenue), pharmaceuticals (15.21%), and leasing and other services (11.51%) [1]. - The company has a total of 27,800 shareholders as of December 31, with an average of 9,545 circulating shares per shareholder, indicating a slight increase in shareholding concentration [2]. - The company has distributed a total of 86.66 million yuan in dividends since its A-share listing, with no dividends paid in the last three years [3].

Group 1 - The core point of the article is that Guanhao Biological has disclosed that as of December 31, 2025, the total number of shareholders will be 27,775 [2]

Core Viewpoint - The A-share market experienced a strong start in 2026, with all major indices rising and the total market capitalization surpassing 120 trillion yuan, marking a historical high [1][6]. Market Performance - On January 5, the Shanghai Composite Index, Shenzhen Component Index, ChiNext Index, and other indices saw increases of 1.38%, 2.24%, 2.85%, and 3.61% respectively, with the Shanghai Composite Index surpassing 4020 points [1][2]. - A total of 4185 stocks rose, with 127 hitting the daily limit, while 1168 stocks declined [2]. - The A-share market's trading volume reached 2.57 trillion yuan, an increase of 501.5 billion yuan from the previous trading day [2]. Sector Performance - The brain-computer interface sector saw significant gains, with companies like Sainuo Medical and Meihao Medical hitting the daily limit of 20% [2]. - Other strong-performing sectors included media, pharmaceuticals, and electronics, with respective increases of 4.12%, 3.85%, and 3.69% [2]. - The non-bank financial sector also rose over 3%, while sectors like oil and gas, banking, and transportation saw slight declines [2]. Funding and Investment Trends - The A-share market's financing balance increased by over 600 billion yuan in December 2025, with a notable rise in net inflows into over 2300 stocks on January 5 [1][3]. - As of December 31, 2025, the A-share margin trading balance reached 25.41 trillion yuan, marking a historical high [4]. - The electronic, defense, and machinery sectors saw significant net buying, while the computer and pharmaceutical sectors experienced net selling [4]. Optimism in Market Sentiment - Analysts noted a shift towards optimistic funding sentiment, with a continuous rise in the Shanghai Composite Index since mid-December 2025 [3][6]. - The market is expected to benefit from long-term capital inflows, particularly from insurance funds, and a favorable global liquidity environment [6][7]. - The upcoming spring market is anticipated to focus on consumption and growth as key themes [6][7].